Etern Therapeutics (Wuxi) Co. Ltd. has synthesized new TNF-α inhibitors potentially useful for the treatment of rheumatoid arthritis, Alzheimer’s disease, cachexia, Blau syndrome, Crohn’s disease, ulcerative colitis, multiple sclerosis and psoriasis, among others.